Table 10 Example of data collection (IPRA Inc 2012)
# | Development stage | Upfront fee | Milestones | Royalty rate | Contract year | SubClass |
|---|---|---|---|---|---|---|
1 | Pre-Clinical or Phase I | $500,000 | 4 % of sales | 2006 | Lyophilized docetaxel | |
2 | Phase I/II | 35 M$ | 372 M$ | Low double digit | 2009 | MEK inhibitors |
3 | Pre-Clinical | $30,000 | $155,000 | 1 %~2 % of sales | 2005 | Immunotherapy |
4 | Pre-Clinical | $100,000 | 8.5 % of sales | 2001 | Platinum complex | |
5 | Pre-Clinical | 3.5 % of sales | 2006 | Pseudomonas exotoxin | ||
6 | Pre-Clinical | 1.5 % of sales | 2002 | Lm-LLO cancer | ||
7 | Phase II | $3,000,000 | 10 M$ | 0 | 1997 | Immune system cancer product |
8 | Phase II | 25 M$ | 400 M$ | 35 % of sales | 2005 | VEGF Trap |